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Autosomal recessive spinal muscular atrophy (SMA) is, after cystic fibrosis, the 
second most common fatal monogenic disorder and the second most common 
hereditary neuromuscular disease after duchenne dystrophy. The disease is 
characterized by degeneration of anterior horn cells leading to progressive 
paralysis with muscular atrophy. Depending on the clinical type (Werdnig-
Hoffmann = type I, intermediate form = type II, Kugelberg-Welander = type 
III), some workers also have delineated an adult form of SMA (SMA type 4). 
SMA causes early death or increasing disability in childhood. The aim of 
this investigation was to describe the clinical findings of patients with spinal 
muscular atrophy (SMA) with survival motor neuron (SMN) gene deletion.
Materials & methods
This is a descriptive study conducted on 10 patients of SMA, confirmed by 
deletion of the SMN gene. All 10 patients had symmetrical muscle weakness, 
which was diffuse in those with onset of symptoms up to 1 months of age, and 
either proximal or predominant in lower limbs. 
Frequency determination of positive clinical and laboratory data was done 
according to revised diagnostic criteria
Results
It was found that all patients with SMA had homozygous deletions of exons 
7 and 8 of the survival motor neuron 1 (SMN1) gene, which is one of the 
candidate genes identified within 5q13. Fasciculations, atrophy and decreased 
DTR were frequent findings. Laboratory metabolic tests and all brain CT 
scans were normal. EMG and NCV findings, all showed normal motor and 
Sensory NCV and denervation of muscles of upper and lower extremities were 
compatible with a diagnosis of spinal muscular atrophy. 
Conclusion
Our results confirm that SMN1 copy number analysis is an important parameter 
for identification of couples at risk of having a child affected with SMA and 
reduces unwarranted prenatal diagnosis for SMA. 
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Introduction
In children the most common entity affecting the motor neuron in the brain stem 
and spinal cord is SMA, with a prevalence of 1 in 10,000 live births and a carrier 
frequency of approximately 1 in 50 (1); proximal spinal muscular atrophy (SMA) 
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represents the second most common fatal autosomal 
recessive disorder after cystic fibrosis (2) and the second 
most common hereditary neuromuscular disease after 
duchenne dystrophy. SMA is characterized by the 
degeneration of anterior horn cells of the spinal cord, 
resulting in progressive weakness. The condition is 
clinically heterogeneous and has been divided into four 
subtypes according to age of onset and clinical severity 
(3). About 10% of infants with SMA type 1 are born with 
arthrogryposis , and this may indicate the severe fetal 
form recently designated type 0 (4,5). Molecular genetic 
analysis has mapped all four forms of childhood and 
adult SMA to chromosome 5q11.2-q13.3, suggesting 
that they are allelic disorders.
In a majority of normal individuals, survival motor 
neuron (SMN) genes are present in at least one telomeric 
(SMN1) and one centromeric (SMN2) copy per 
chromosome. However, 26% of all normal chromosomes 
5 lack the SMN2 copy of the gene. The two SMN genes 
are highly homologous but a single nucleotide variation 
in exon 7 of SMN1 and SMN2 genes is responsible for 
functional differences (6). The majority of SMA patients, 
irrespective of their clinical types, have homozygous 
deletion of the SMN1 gene (7). In addition intragenic 
mutations have been identified in most of the patients 
who have only one copy of SMN1 gene, confirming the 
involvement of SMN1 in the pathogenesis of SMA (8). 
Normal individuals with one copy of the SMN1 gene are 
carriers for this autosomal recessive disorder.
The single nucleotide differences in exons 7 and 8 are 
used to distinguish SMN1 and SMN2 in diagnostic 
and prenatal testing for SMA (9,10). Although this 
methodology can detect homozygous absence of SMN1, 
it cannot differentiate the presence of one copy from 
two or more copies of SMN1. In recent years, molecular 
diagnostic testing for SMN1 copy number by dosage 
analysis has been developed (11,12), and is used to 




Detailed clinical history and pedigree was drawn for all 
cases and their families. Clinical examinations of patients 
and family members were carried out in the neurology 
outpatient department of the Amirkola pediatric hospital. 
Informed consents were obtained for all participants, 
following genetic counseling. Eventually ten children, 
four female and 6 male, were included in the study. 
Results
Mean age at time of diagnosis of the 10 infants was 4 
months. All had symmetrical muscle weakness, which 
was diffuse in those with onset of symptoms up to 1 
month of age, and either proximal or predominant in 
lower limbs .It was found that all patients with SMA had 
homozygous deletions of exons 7 and 8 of the survival 
motor neuron 1 (SMN1) gene, i.e. one of the candidate 
genes identified within 5q13. Fasciculations, atrophy 
and decreased DTR were frequent findings.Laboratory 
metabolic tests and all brain CT scans were normal. 
EMG and NCV findings, all showed normal motor 
and sensory nerve conduction velocity (SNCV) and 
denervation of muscles of upper and lower extremities 
that were compatible with a diagnosis of spinal muscular 
atrophy.
Discussion
Ten samples were analyzed by quantitative PCR to 
determine the number of SMN1 gene copies present, 
and all of these were found to have one SMN1 gene 
copy. A previous study reported that 94.3% of normal 
individuals had two SMN1 copies and 2.1%, 0.7% and 
2.9% had three, four and one copy (ies), respectively 
[13]. Only one SMN1 gene copy is sufficient for normal 
functioning in an individual, as all parents with one copy 
of the SMN1 gene are asymptomatic.
From our small group of SMA cases, parents of confirmed 
SMA patients were obligate carriers of the disease, 
which was confirmed by SMA carrier testing; however, 
parents of children with SMA may not always be carriers 
as de-novo deletions of the SMN1 gene occurs in more 
than 2% of patients, with SMA (12,14). Presence of 
de-novo deletion in the family lowers the recurrence 
risk for couples from 25% to the risk of a second de-
novo mutation which is very low. Knowledge of the 
carrier status of parents of affected children is useful 
for determining if a de-novo mutation has occurred and 
establishing the couple’s future risk of having an affected 
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child. If the parents are found to be carriers, then carrier 
testing can be offered to the siblings of the parents, who 
also have a 50% risk of being a carrier for SMA (1).
The most severe form of SMA occurs at birth or in early 
infancy and in Iran this may be difficult for primary 
care providers to diagnose. No data are available on the 
population prevalence of SMA and the status of diagnosis 
of SMA from Iran, due to the limited number of centers 
and the high cost and complexity of the molecular 
genetic test. Hence unfortunately in many cases the 
child usually expires before the diagnosis is confirmed 
and the parents refer with a history of a previous child’s 
death with symptoms consistent with SMA. In absence 
of a sample for molecular genetic testing for SMA, the 
information obtained by SMN1 copy number analysis 
for the parents can be utilized to confirm the diagnosis 
for the deceased child and to offer prenatal diagnosis 
for future pregnancies. The presence of one copy of 
the SMN1 gene in the parents will confirm their carrier 
status and prenatal diagnosis can definitely be advised 
in subsequent pregnancies. Our results confirm that 
SMN1 copy number analysis is an important parameter 
for identification of couples at risk for having a child 
affected with SMA and reduces unwarranted birth of 
children with dignosis of SMA. Copy number analysis 
is also useful in the setting of clinically suspected SMA 
with a negative diagnostic SMA test.
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